These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15329529)

  • 21. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy.
    Shikuma CM; Hu N; Milne C; Yost F; Waslien C; Shimizu S; Shiramizu B
    AIDS; 2001 Sep; 15(14):1801-9. PubMed ID: 11579242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipodystrophy syndrome among HIV infected children on highly active antiretroviral therapy in northern India.
    Bhutia E; Hemal A; Yadav TP; Ramesh KL
    Afr Health Sci; 2014 Jun; 14(2):408-13. PubMed ID: 25320591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection.
    Barbaro G
    Curr HIV Res; 2006 Jan; 4(1):79-85. PubMed ID: 16454713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.
    Hammond E; McKinnon E; Nolan D
    Clin Infect Dis; 2010 Sep; 51(5):591-9. PubMed ID: 20645860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy.
    Resino S; Micheloud D; Lorente R; Bellon JM; Navarro ML; Munoz-Fernandez MA
    HIV Med; 2011 Jan; 12(1):54-60. PubMed ID: 20497248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case-control study of HIV-associated pancreatic abnormalities during HAART era. Focus on emerging risk factors and specific management.
    Manfredi R; Calza L; Chiodo F
    Eur J Med Res; 2004 Dec; 9(12):537-44. PubMed ID: 15689299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study.
    Mercier S; Gueye NF; Cournil A; Fontbonne A; Copin N; Ndiaye I; Dupuy AM; Cames C; Sow PS; Ndoye I; Delaporte E; Simondon KB
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):224-30. PubMed ID: 19339897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipodystrophy and metabolic complications of highly active antiretroviral therapy.
    Parakh A; Dubey AP; Kumar A; Maheshwari A
    Indian J Pediatr; 2009 Oct; 76(10):1017-21. PubMed ID: 19907933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dyslipidemia in HIV Infected Children Receiving Highly Active Antiretroviral Therapy.
    Mandal A; Mukherjee A; Lakshmy R; Kabra SK; Lodha R
    Indian J Pediatr; 2016 Mar; 83(3):226-31. PubMed ID: 26334860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.
    d'Arminio Monforte A; Lepri AC; Rezza G; Pezzotti P; Antinori A; Phillips AN; Angarano G; Colangeli V; De Luca A; Ippolito G; Caggese L; Soscia F; Filice G; Gritti F; Narciso P; Tirelli U; Moroni M
    AIDS; 2000 Mar; 14(5):499-507. PubMed ID: 10780712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics and factors associated with the clinical forms of lipoatrophy during highly active antiretroviral therapy in Ouagadougou, Burkina Faso.
    Guira O; Tiéno H; Yaméogo B; Diendéré AE; Korsaga N; Sagna Y; Zoungrana L; Diallo I; Traoré R; Drabo JY
    J Int Assoc Provid AIDS Care; 2014; 13(2):184-7. PubMed ID: 24114724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report.
    Saka B; Akakpo AS; Bassowa A; Dapam AN; Mahamadou G; Teclessou JN; Mouhari-Toure A; Laouali AY; Mensah E; Kombaté K; Pitché P
    Ann Dermatol Venereol; 2018 Dec; 145(12):773-776. PubMed ID: 30301570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.
    Fantoni M; Del Borgo C; Autore C; Barbaro G
    Ital Heart J; 2002 May; 3(5):294-9. PubMed ID: 12066561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case-control study of gynecomastia in HIV-1-infected patients receiving HAART.
    Rahim S; Ortiz O; Maslow M; Holzman R
    AIDS Read; 2004 Jan; 14(1):23-4, 29-32, 35-40. PubMed ID: 14959701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of APOC3 polymorphisms with both dyslipidemia and lipoatrophy in HAART-receiving patients.
    Bonnet E; Bernard J; Fauvel J; Massip P; Ruidavets JB; Perret B
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):169-71. PubMed ID: 18240956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gynaecomastia associated with saquinavir therapy.
    Donovan B; Bodsworth NJ; Mulhall BP; Allen D
    Int J STD AIDS; 1999 Jan; 10(1):49-50. PubMed ID: 10215131
    [No Abstract]   [Full Text] [Related]  

  • 39. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.
    Galli M; Ridolfo AL; Adorni F; Cappelletti A; Morelli P; Massetto B; Piazza M; Gianelli E; Vaccarezza M; Gervasoni C; Moroni M
    Antivir Ther; 2003 Aug; 8(4):347-54. PubMed ID: 14518704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
    van der Valk M; Gisolf EH; Reiss P; Wit FW; Japour A; Weverling GJ; Danner SA;
    AIDS; 2001 May; 15(7):847-55. PubMed ID: 11399957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.